The efficacy and safety of pimecrolimus 1% cream was evaluated in 45 patients with relapsing seborrheic dermatitis (SD) that had been previously treated with this agent. Disease severity, complete cure, remission times and side effects were recorded. Pimecrolimus was applied b.i.d. until the lesions healed completely. Patients were evaluated before the first and second treatments and disease severity recorded on a 0-3 scale (where 0 = absent and 3 = severe). Disease and erythema severity were significantly decreased by a second treatment with pimecrolimus. Mean area affected, cure time and time in remission were also significantly decreased by pimecrolimus and thus it could be used for maintenance treatment or prophylaxis in ...